MedPath

Norethisterone

Generic Name
Norethisterone
Brand Names
Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Emzahh 28 Day, Errin 28 Day, Estalis, Etyqa 0.5/0.1 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Finzala 24 Fe Chewable 28 Day, Fyavolv, Gemmily 28 Day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Rhuzdah 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent
Drug Type
Small Molecule
Chemical Formula
C20H26O2
CAS Number
68-22-4
Unique Ingredient Identifier
T18F433X4S
Background

Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and its derivatives, and is the active form of several other progestins including norethynodrel and lynestrenol. Norethisterone mimics the actions of endogenous progesterone, albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy. First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.

Indication

Norethisterone is indicated as an oral contraceptive when given as monotherapy or in combination with an estrogen component, such as ethinylestradiol or estradiol. In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause. When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.

Norethisterone, taken in combination with intramuscular leuprolide, is also indicated for the symptomatic treatment of endometriosis-related pain.

Associated Conditions
Endometriosis related pain, Heavy Menstrual Bleeding, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Postmenopausal Osteoporosis, Severe Pain, Vulvo Vaginal Atrophy, Hypoestrogenism, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Hormone Replacement Therapy, Oral Contraceptives

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

Early Phase 1
Recruiting
Conditions
Arginine Vasopressin Deficiency
Oxytocin Deficiency
Interventions
First Posted Date
2024-06-14
Last Posted Date
2025-02-11
Lead Sponsor
Elizabeth Austen Lawson
Target Recruit Count
32
Registration Number
NCT06460948
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Phase 3
Recruiting
Conditions
Endometriosis
Interventions
First Posted Date
2024-06-03
Last Posted Date
2024-12-06
Lead Sponsor
Main Line Health
Target Recruit Count
110
Registration Number
NCT06439524
Locations
🇺🇸

Main Line Health, Wynnewood, Pennsylvania, United States

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Not yet recruiting
Conditions
Bleeding Disorder
Heavy Menstrual Bleeding
Von Willebrand Diseases
Interventions
First Posted Date
2023-06-23
Last Posted Date
2023-06-23
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
300
Registration Number
NCT05916469

Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy

First Posted Date
2022-10-19
Last Posted Date
2024-06-04
Lead Sponsor
Angelica Lindén Hirschberg
Target Recruit Count
520
Registration Number
NCT05586724
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Sweden

The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis

Not Applicable
Completed
Conditions
Endometriosis
Interventions
First Posted Date
2022-07-27
Last Posted Date
2023-07-21
Lead Sponsor
Uludag University
Target Recruit Count
70
Registration Number
NCT05476172
Locations
🇹🇷

Uludag University, Bursa, Nilufer, Turkey

Effects of One-to-one Service on the Continuation and Satisfaction of Contraceptive Use.

Not Applicable
Conditions
Contraceptive Usage
Contraception Behavior
Interventions
Other: Family Planning Service
Other: One-to-one Service
First Posted Date
2022-05-05
Last Posted Date
2022-05-05
Lead Sponsor
National Research Institute for Family Planning, China
Target Recruit Count
400
Registration Number
NCT05362019
Locations
🇨🇳

Qinghai Red Cross Hospital, Xining, Qinghai, China

🇨🇳

Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, Tianjin, China

🇨🇳

Yunnan Xishuangbanna people's Hospital, Xishuangbanna, Yunnan, China

and more 5 locations

A Trial of Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts

Phase 4
Conditions
Ovarian Cyst Simple
Interventions
First Posted Date
2022-03-24
Last Posted Date
2022-03-24
Lead Sponsor
Assiut University
Target Recruit Count
66
Registration Number
NCT05293574

Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate

Phase 4
Completed
Conditions
Contraception
Interventions
First Posted Date
2022-03-24
Last Posted Date
2024-07-16
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
6
Registration Number
NCT05294341
Locations
🇺🇸

Hershey Medical Center, Hershey, Pennsylvania, United States

Management of Uterine Leiomyomata and Adenomyosis

Conditions
Abnormal Uterine Bleeding
Interventions
First Posted Date
2021-12-10
Last Posted Date
2021-12-10
Lead Sponsor
Ahmed Ali Mahmoud
Target Recruit Count
100
Registration Number
NCT05153928
Locations
🇪🇬

Ahmed Ali, Assiut, Egypt

🇪🇬

Maternaty hospital in assiut, Assiut, Egypt

Effectiveness of Hormonal Intrauterine Device in Treating PCS Compared to Oral Progestin

Not Applicable
Completed
Conditions
Pelvic Congestion
Interventions
Device: Hormonal intrauterine device
First Posted Date
2021-09-20
Last Posted Date
2023-07-21
Lead Sponsor
Assiut University
Target Recruit Count
104
Registration Number
NCT05050357
Locations
🇪🇬

Sohag, Sohag, Egypt

© Copyright 2025. All Rights Reserved by MedPath